Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 1

1(16.7%)

6Total

N/A(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01568567Phase 1Completed

Study to Demonstrate the Safety of a Novel Powder Formulation of Lactobacilli in Adults

Role: lead

NCT01033539Not ApplicableCompleted

To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans

Role: lead

NCT01102036Not ApplicableCompleted

Effects of Cultura Yoghurt in Relation to Transit Time and Digestive Discomfort in Healthy Women and Men

Role: lead

NCT01127828Not ApplicableCompleted

Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes

Role: lead

NCT01117363Not ApplicableUnknown

Effect of Three Weeks Consumption of Rye Porridge Breakfast

Role: collaborator

NCT00876785Not ApplicableCompleted

Effect of Rye Bread Breakfasts on Eight Hour Satiety Ratings

Role: collaborator

All 6 trials loaded